Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF). Although NOACs substantially reduce intracranial hemorrhage, upper gastrointestinal bleeding (UGIB) remains a frequent and clinically consequential complication. Proton pump inhibitors (PPIs) may reduce UGIB risk; however, concerns regarding long-term safety and pharmacodynamic variability persist. Fexuprazan, a potassium-competitive acid blocker (P-CAB), provides rapid and sustained acid suppression independent of acid activation and CYP2C19 metabolism. No randomized trial has evaluated P-CAB therapy for prevention of UGIB in anticoagulated patients.
Methods FENOX is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) superiority trial. Approximately 1,000 high-risk patients with non-valvular AF initiating NOAC therapy will be randomized 1:1 to receive fexuprazan plus NOAC therapy or NOAC therapy alone. High-risk enrichment includes advanced age, renal impairment, concomitant antiplatelet therapy, prior ulcer disease, or elevated HAS-BLED score. The primary endpoint is clinically relevant upper gastrointestinal bleeding (CR-UGIB) at 12 months, defined according to ISTH criteria. All events will be adjudicated by an independent blinded Clinical Events Committee. Primary analyses will follow the intention-to-treat principle using time-to-event methods.
Results The planned sample size provides 80% power to detect a 50% relative risk reduction in CR-UGIB, assuming a 12-month incidence of 10% in the control group. Interim safety monitoring will be conducted under independent oversight.
Conclusion FENOX is the first randomized trial designed to evaluate a P-CAB-based gastroprotective strategy for prevention of clinically relevant UGIB in high-risk patients receiving NOAC therapy. By integrating high-risk enrichment, pragmatic design, and blinded endpoint adjudication, the study aims to provide rigorous evidence to inform gastroprotective strategies in anticoagulated populations.

Start Date01 Dec 2026

Sponsor / Collaborator

Ewha Womans University Mokdong Hospital

NCT07730138

/ Not yet recruitingPhase 3

A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants With Gastric Ulcer

A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer

Start Date15 Oct 2026

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

NCT07746518

/ Not yet recruitingPhase 3

A Multi-center, Double-blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial and Open-label Extension Study to Evaluate the Efficacy and Safety of DWP14012 for Maintenance Therapy in Patients With Healed Erosive Esophagitis

Start Date01 Sep 2026

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Fexuprazan hydrochloride

100 Translational Medicine associated with Fexuprazan hydrochloride

100 Patents (Medical) associated with Fexuprazan hydrochloride

Literatures (Medical) associated with Fexuprazan hydrochloride

01 Nov 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of highly selective and potent CYP1B1 inhibitors for overcoming paclitaxel resistance in A549/Taxol cells

Article

Author: Wang, Ting ; Liu, Xiaoqiu ; Cheng, Maosheng ; Tan, Dihan ; Fu, Yujiang ; Song, Bohou ; Qin, Ningyi ; Zhang, Haoyu

Recent studies have demonstrated that CYP1B1 plays a crucial role in tumor drug resistance. Paclitaxel, a first-line chemotherapeutic agent for solid tumors such as non-small cell lung cancer, often encounters limitations in clinical efficacy due to drug resistance. Notably, CYP1B1 is significantly upregulated in paclitaxel-resistant cells, and its inhibition has been shown to effectively enhance the sensitivity of these resistant cells to paclitaxel. Our research group previously identified W-1, a key intermediate of Fexuprazan, as an inhibitor of CYP1B1 (IC₅₀ = 0.16 μM). Building upon this lead compound, we designed and synthesized 52 target compounds through structural optimization. Systematic screening yielded multiple highly active and selective CYP1B1 inhibitors. Among these, the preferred compound C27 exhibited an IC₅₀ value of 1.47 nM against CYP1B1 and demonstrated high selectivity over six major CYP isoforms. In the A549/Taxol drug-resistant cell model, C27 significantly enhanced the inhibitory effect of paclitaxel on the proliferation of resistant cells and effectively inhibited tumor cell migration and invasion. Pharmacokinetic studies revealed that C27 displayed good plasma stability and liver microsomal stability, with observable systemic exposure following both oral and intravenous administration in mice.

11 Sep 2026·MEDICINE

Randomized controlled trial comparing 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication

Article

Author: Park, Sung Chul ; Lee, Sung Joon ; Nam, Seung-Joo ; Kim, Ji Hyun ; Lee, Jung Ho ; Kim, San Ha ; Lee, Sang Hoon

Background::

Fexuprazan is a newly developed potassium-competitive acid blocker used for the treatment of acid-related gastrointestinal diseases; however, clinical data regarding its efficacy in Helicobacter pylori eradication are lacking. This study evaluated the efficacy and safety of a 7-day fexuprazan-based triple therapy regimen compared with a 14-day rabeprazole-based triple therapy regimen for H. pylori infection in Korean patients.

Methods::

A randomized controlled single-center study was conducted to compare the eradication rates between 7-day fexuprazan (40 mg)-based triple therapy (with 1 g amoxicillin and clarithromycin 500 mg administered twice daily) and 14-day rabeprazole (20 mg)-based triple therapy for H. pylori eradication. The primary endpoint was the success rate of H. pylori eradication, determined using the 13C-urea breath test. Safety outcomes were also evaluated.

Results::

A total of 79 patients were randomly assigned to the fexuprazan and rabeprazole groups. In the full analysis set, eradication rates were 80.00% (32/40) in the fexuprazan group and 82.05% (32/39) in the rabeprazole group. In the per-protocol set, eradication rates were 83.78% (31/37) and 88.89% (32/36), respectively ( P = 1.000 and P =.737). The overall incidence of treatment-emergent adverse events was 70.00% (28/40) in the fexuprazan group and 66.67% (26/39) in the rabeprazole group, with no significant difference between groups ( P =.812); both regimens were well tolerated. Among patients with clarithromycin-susceptible strains in full analysis set, eradication rates were 93.10% (27/29) in the fexuprazan group and 87.09% (27/31) in the rabeprazole group ( P =.672). In the per-protocol set, eradication rates for susceptible strains were 96.42% (27/28) in the fexuprazan group and 93.10% (27/29) in the rabeprazole group ( P = 1.000).

Conclusion::

Seven-day fexuprazan-based triple therapy demonstrated eradication efficacy comparable with that of 14-day rabeprazole-based therapy in treatment-naïve Korean patients with H. pylori infection. The fexuprazan-based regimen showed a similar safety profile and comparable incidence of adverse events with that of the rabeprazole-based regimen.

01 Aug 2026·The Journal of the Association of Physicians of India

Redefining Acid Suppression in Acid Peptic Disorders: The Emerging Role of Prazans

Review

Author: Sethi, Sushant Kumar ; Puri, Rajesh ; Muthuswamy, Hariharan ; Vg, Mohan ; Bs, Ravindra ; Pal, Sandip ; Ranjan, Piyush ; Pratap, Nitesh ; B, Ravishankar ; Yadav, Devesh ; Singla, Vikas ; Kanuru, Vasu Praveen Chander ; Kak, Manish ; Panigrahi, Manas Kumar ; Ghoshal, Uday C ; Goenka, Mahesh ; Lawate, Parimal

Abstract:

Acid peptic disorders (APDs) affect approximately 38% of the population in India and commonly present with overlapping phenotypes, including gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease (PUD), necessitating uniform and sustained acid suppression. Proton pump inhibitors (PPIs) have several clinical limitations, including a delayed onset of action of 3-5 days, incomplete 24-hour acid control with nocturnal acid breakthrough, high nonresponse rates of approximately 40% in GERD and 37% in nonerosive reflux disease (NERD), and variability related to cytochrome P450 2C19 (CYP2C19) metabolism, meal dependency, and drug interactions. Collectively, these limitations contribute to inconsistent real-world efficacy.

Potassium-competitive acid blockers:

Mechanistic and pharmacodynamic superiority: Potassium-competitive acid blockers (P-CABs) directly and reversibly inhibit the H+/K+-ATPase without requiring acid activation, thereby enabling a rapid onset of action from the first dose. Inhibition of both active and inactive proton pumps provides continuous and sustained acid suppression. P-CABs offer true 24-hour intragastric pH control, including nocturnal control, with a higher parietal-cell concentration of approximately 100,000-fold compared with approximately 1,000-fold for PPIs. Their meal-independent administration, low CYP-related variability, and minimal potential for drug interactions allow a more predictable response across patient populations.

Tegoprazan:

Rapid onset, nocturnal control, and comorbidity advantages-Tegoprazan may be considered in the following clinical settings: symptomatic GERD and on-demand treatment of GERD/NERD, because its rapid onset of action within approximately 30 minutes may facilitate early symptom relief and flexible dosing; nocturnal acid breakthrough, because it provides nocturnal pH control, with an intragastric pH of ≥4 maintained for approximately 66% of the night; patients at cardiovascular risk receiving antiplatelet therapy, dual antiplatelet therapy, or atorvastatin, because its lower interaction potential involving CYP2C19 and CYP3A4 may reduce the risk of gastrointestinal bleeding and treatment failure related to dyslipidemia; and patients with renal or metabolic comorbidities, because it has shown favorable renal safety signals and a lower decline in serum creatinine levels.

Vonoprazan:

Potency, high acid burden, and eradication efficacy-Vonoprazan may be preferred in the following situations: refractory GERD after PPI failure, because its potent and sustained acid suppression may overcome an inadequate response to PPIs; severe GERD and other high-acid-burden states, because it provides consistent and prolonged intragastric pH elevation; Helicobacter pylori eradication, because it may serve as a preferred treatment backbone, with reported eradication rates of approximately 92.6% through sustained maintenance of an intragastric pH >6; nonsteroidal anti-inflammatory drug-associated ulcers, because it may reduce ulcer recurrence and the risk of gastrointestinal bleeding; complex or recurrent PUD, because its stronger acid suppression may support faster and more durable healing; and hepatic disease, because it has demonstrated favorable outcomes, with fewer liver-related complications than PPIs.

Fexuprazan—Stability and extraesophageal reflux phenotypes:

Fexuprazan may be considered for extraesophageal reflux, including laryngopharyngeal reflux and atypical GERD, because it has been associated with improvements in reflux symptom indices and airway-related symptoms.

Conclusion:

Tegoprazan may be preferred when rapid symptom relief, nocturnal acid control, and a favorable drug-interaction profile are required. Vonoprazan may be preferred when maximal acid suppression and enhanced H. pylori eradication efficacy are needed. Fexuprazan may be considered for laryngopharyngeal reflux and other atypical or extraesophageal GERD phenotypes.

News (Medical) associated with Fexuprazan hydrochloride

11 Jun 2025

·pipelinereview.com

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

– The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical’s drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea I June 11, 2025 I Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech’s expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong’s development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. “We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical’s pipeline”, said Jens Frauenfeld, CEO of Salipro Biotech. “This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable.” Seongsoo Park, CEO at Daewoong Pharmaceutical stated, “Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro’s expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts.” About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company’s diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. SOURCE: Daewoong Pharmaceutical Co.

Orphan DrugFast Track

11 Jun 2025

·www.prnewswire.com

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Continue Reading Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. SOURCE Daewoong Pharmaceutical Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan DrugFast Track

07 Apr 2025

·pharma.economictimes.indiatimes.com

Sun Pharma launches its novel licensed brand Fexuclue in India

Mumbai: Indian drug maker, Sun Pharma has launched its its brand Fexuclue tablets version Fexuclue, a novel potassium competitive acid blocker , indicated for the treatment of adults with Erosive Esophagitis of all grades. The drug is marketed by Daewoong Pharmaceutical and Sun Pharma has obtained India rights through a licensing deal under which the Korean-drug maker is entitled to upfront and milestone payments, including royalties. "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management but Fexuclue, is a best-in-class treatment option with the potential to bridge this gap," said Kirti Ganorkar, CEO, India Business, Sun Pharma. In a stock exchange filing, Sun Pharma shared that, “the drug was evaluated in a double-blind, double-dummy, comparative Phase 3 study in adult Indian population and the primary efficacy measure was healing of Erosive Esophagitis which was confirmed endoscopically and was was found to be well tolerated in Indian patients.” “The study met its primary endpoint, where over 95 per cent of the patients achieved Erosive Esophagitis healing by eight weeks,” it added. By Online Bureau ,

Phase 3Clinical ResultLicense out/inDrug Approval

100 Deals associated with Fexuprazan hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D13012	-	A02BC10	DB16078

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peptic Ulcer	South Korea	Daewoong Pharmaceutical Co., Ltd.	12 May 2025
Gastroesophageal Reflux	South Korea	Daewoong Pharmaceutical Co., Ltd.	30 Dec 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stomach Ulcer	Phase 3	Indonesia	Daewoong Pharmaceutical Co., Ltd.	15 Oct 2026
Stomach Ulcer	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	15 Oct 2026
Helicobacter pylori infection	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	06 Feb 2024
Esophagitis, Peptic	Phase 3	China	Daewoong Pharmaceutical Co., Ltd.	30 Dec 2021
Gastritis	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	02 Jun 2020
Non-erosive gastro-esophageal reflux disease	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	07 Feb 2019
Non-erosive reflux disease	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	07 Feb 2019
Erosive gastro-esophageal reflux disease	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	13 Dec 2018
Erosive esophagitis	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	13 Dec 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT07326904 (CTgov)	Phase 3	Gastroesophageal Reflux	145	Fexuprazan (Fexuprazan 40 mg)	bhqnigzgku = qhdlmeibxy gvpinjlkce (ikjibglmpp, hkomyhncio - yfnawliszb) View more	-	24 Aug 2026
				Esomeprazole (Esomeprazole 40 mg)	bhqnigzgku = mpmrltfdxp gvpinjlkce (ikjibglmpp, jabebkmnyv - jbihzkofnv) View more
DDW2026	Phase 3	Helicobacter pylori infection First line	461	Fexuprazan 40 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg	fdrqtqxacy(meyhpqxfhs) = ufzmsctlbh jzbuhdguzt (fpqnivqskp ) View more	Non-inferior	02 May 2026
				Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg	fdrqtqxacy(meyhpqxfhs) = jbjvzixpbp jzbuhdguzt (fpqnivqskp ) View more
WCN2025	Not Applicable	Gastroesophageal Reflux \| Acute Ischemic Stroke	18	Fexuprazan + Fexuprazanotic agents	xlwwmpvsfa(gdrafwmuro) = ttaojxqftf lwyaahrohz (ugivvjzvwd, 1.7) View more	Positive	12 Oct 2025
NCT04784910 (Pubmed \| Gut Liver)	Phase 3	-	-	Fexuprazan 20 mg/day	rpldyswwgm(upicbfictl) = lhbihattjo mvnpgexixx (svrhytyzvc ) View more	Positive	15 Sep 2025
				Lansoprazole 15 mg/day	rpldyswwgm(upicbfictl) = fyneusjawr mvnpgexixx (svrhytyzvc ) View more
NCT04784910 (DDW2025)	Phase 3	Peptic Ulcer	423	Fexuprazan 20 mg/day	voprttisgh(oungkiycda) = xljuueyvos xtxbcwbhzi (tahgmfdavd ) View more	Non-inferior	03 May 2025
				Lansoprazole 15 mg/day	voprttisgh(oungkiycda) = xexruflcsy xtxbcwbhzi (tahgmfdavd ) View more
NEWS	-	Esophagitis, Peptic	513	非苏拉生	jxapdwutrw(vysvictris) = acidplasnn ycozxwhoft (sonauvgwcd ) View more	Non-inferior	17 Oct 2024
				艾司奥美拉唑	jxapdwutrw(vysvictris) = trghcehqii ycozxwhoft (sonauvgwcd ) View more
UEGW2024	Not Applicable	-	-	Fexuprazan 40 mg	pnelljtljr(gpjfcxzoxn) = qghzaenpml tifiuazumd (kjyyykotwb, -2.80 to 9.23) View more	-	13 Oct 2024
				Esomeprazole 40 mg	pnelljtljr(gpjfcxzoxn) = zbqgnnbqel tifiuazumd (kjyyykotwb, -2.80 to 9.23) View more
NCT05813561 (Pubmed) Manual	Phase 3	Erosive esophagitis	332	Fexuprazan 40 mg	phqojuflts(oekbdgpvka) = bzlbswoxnw lmahylcelt (apolnekaql ) View more	Positive	22 Jan 2024
				Esomeprazole 40 mg	phqojuflts(oekbdgpvka) = xmqoneutir lmahylcelt (apolnekaql ) View more
NCT04341454 (Pubmed \| Gut Liver)	Phase 3	Acute gastritis \| Chronic gastritis	327	Fexuprazan 20 mg q.d.	fhqrkpnpxi(vhiupdgawh) = swrjdyagks zxdgdxlxqy (khjbsmnkao )	-	15 Feb 2023
				Fexuprazan 10 mg b.i.d.	fhqrkpnpxi(vhiupdgawh) = imvalzmmwi zxdgdxlxqy (khjbsmnkao )
UEGW2022	Not Applicable	Acute gastritis \| Chronic gastritis	-	Fexuprazan 20 mg q.d.	ixumsgfasa(qxlwaxgubz) = imaotmpqrs gwmudpyqyi (kcoznvkodl )	-	09 Oct 2022
				Fexuprazan 10 mg b.i.d.	ixumsgfasa(qxlwaxgubz) = pjgsiwuils gwmudpyqyi (kcoznvkodl )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis